KP
IDXX icon

Keel Point’s Idexx Laboratories IDXX Stock Holding History

Keel Point’s Portfolio IDXX Stock Details IDXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$223K Buy
424
+14
+3% +$7.85K 0.01% 457
2026
Q1 		$230K Sell
410
-218
-35% -$140K 0.02% 410
2025
Q4 		$425K Sell
628
-50
-7% -$34.1K 0.03% 334
2025
Q3 		$433K Buy
678
+65
+11% +$39.5K 0.03% 330
2025
Q2 		$329K Sell
613
-20
-3% -$9.56K 0.02% 380
2025
Q1 		$266K Buy
+633
New +$275K 0.02% 374
2024
Q4 		– Sell
-594
Closed -$300K – 457
2024
Q3 		$300K Buy
594
+18
+3% +$8.74K 0.03% 327
2024
Q2 		$281K Buy
576
+49
+9% +$24.6K 0.03% 330
2024
Q1 		$285K Buy
527
+49
+10% +$26.8K 0.03% 293
2023
Q4 		$265K Sell
478
-12
-2% -$5.63K 0.03% 279
2023
Q3 		$214K Sell
490
-12
-2% -$5.98K 0.03% 291
2023
Q2 		$252K Buy
502
+68
+16% +$32.6K 0.03% 269
2023
Q1 		$217K Buy
+434
New +$208K 0.03% 281
2021
Q2 		– Sell
-470
Closed -$230K – 293
2021
Q1 		$230K Buy
+470
New +$235K 0.02% 241

Other funds holding IDXX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Keel Point's IDXX Position: Q2 2026 in Review

Keel Point increased its Idexx Laboratories (IDXX) stake by 3.4% in Q2 2026, buying an estimated $7.85K and bringing the position to 424 shares worth $223K. The position accounts for 0.01% of the portfolio, ranked #457.

Keel Point first reported a position in IDXX in Q1 2021 and has held it in 14 quarters since. The position peaked at $433K in Q3 2025. 1,302 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.

  • Keel Point held 424 shares of Idexx Laboratories worth $223K as of Q2 2026.
  • Keel Point bought 14 Idexx Laboratories shares in Q2 2026, an estimated $7.85K.
  • Idexx Laboratories made up 0.01% of Keel Point's portfolio in Q2 2026, its #457 holding.
  • Keel Point first reported a position in Idexx Laboratories in Q1 2021 and has held it in 14 quarters since.
  • Keel Point's Idexx Laboratories position peaked at $433K in Q3 2025.
  • 1,302 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.

Based on Keel Point's 13F filing for Q2 2026, filed 14 Aug 2026.